PDF(Pubmed)
Abstract：
UNASSIGNED: Long-term symptoms after a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (ie, post-coronavirus disease 2019 [COVID-19] condition or long COVID) constitute a substantial public health problem. Yet, the prevalence remains currently unclear as different case definitions are used, and negatively tested controls are lacking. We aimed to estimate post-COVID-19 condition prevalence using 6 definitions.
UNASSIGNED: The Prevalence, Risk factors, and Impact Evaluation (PRIME) post-COVID-19 condition study is a population-based sample of COVID-19-tested adults. In 2021, 61 655 adults were invited to complete an online questionnaire, including 44 symptoms plus a severity score (0-10) per symptom. Prevalence was calculated in both positively and negatively tested adults, stratified by time since their COVID-19 test (3-5, 6-11, or ≥12 months ago).
UNASSIGNED: In positive individuals (n = 7405, 75.6%), the prevalence of long-term symptoms was between 26.9% and 64.1% using the 6 definitions, while in negative individuals (n = 2392, 24.4%), the prevalence varied between 11.4% and 32.5%. The prevalence of long-term symptoms potentially attributable to COVID-19 ranged from 17.9% to 26.3%.
UNASSIGNED: There is a (substantial) variation in prevalence estimates when using different post-COVID-19 condition definitions, as is current practice; there is limited overlap between definitions, indicating that the essential post-COVID-19 condition criteria are still unclear. Including negatives is important to determine long-term symptoms attributable to COVID-19.
UNASSIGNED: ClinicalTrials.gov Identifier: NCT05128695.
UNASSIGNED: The Prevalence, Risk factors, and Impact Evaluation (PRIME) post-COVID-19 condition study is a population-based sample of COVID-19-tested adults. In 2021, 61 655 adults were invited to complete an online questionnaire, including 44 symptoms plus a severity score (0-10) per symptom. Prevalence was calculated in both positively and negatively tested adults, stratified by time since their COVID-19 test (3-5, 6-11, or ≥12 months ago).
UNASSIGNED: In positive individuals (n = 7405, 75.6%), the prevalence of long-term symptoms was between 26.9% and 64.1% using the 6 definitions, while in negative individuals (n = 2392, 24.4%), the prevalence varied between 11.4% and 32.5%. The prevalence of long-term symptoms potentially attributable to COVID-19 ranged from 17.9% to 26.3%.
UNASSIGNED: There is a (substantial) variation in prevalence estimates when using different post-COVID-19 condition definitions, as is current practice; there is limited overlap between definitions, indicating that the essential post-COVID-19 condition criteria are still unclear. Including negatives is important to determine long-term symptoms attributable to COVID-19.
UNASSIGNED: ClinicalTrials.gov Identifier: NCT05128695.
摘要：
■严重急性呼吸道综合症冠状病毒2（SARS-CoV-2）感染后的长期症状（即，2019年冠状病毒病后[COVID-19]病症或长期COVID)构成了重大的公共卫生问题。然而，流行率目前仍不清楚，因为使用了不同的病例定义，缺乏负面测试的对照。我们的目的是使用6个定义来估计COVID-19后的患病率。
■患病率，危险因素,COVID-19后病情研究和影响评估（PRIME）是一项基于人群的COVID-19测试成年人样本。2021年，61655名成年人被邀请完成在线调查问卷，包括44个症状加上每个症状的严重程度评分（0-10）。患病率是在阳性和阴性测试的成年人中计算的，按COVID-19测试以来的时间分层（3-5、6-11或≥12个月前）。
■在阳性个体中（n=7405，75.6％），根据6个定义，长期症状的患病率在26.9%至64.1%之间，而在阴性个体中(n=2392，24.4%)，患病率在11.4%和32.5%之间。可能归因于COVID-19的长期症状的患病率为17.9%至26.3%。
■当使用不同的COVID-19后条件定义时，患病率估计值存在（实质性）差异，正如目前的做法一样；定义之间存在有限的重叠，这表明COVID-19后的基本病情标准仍不清楚。包括阴性对于确定可归因于COVID-19的长期症状很重要。
■ClinicalTrials.gov标识符：NCT05128695。
■患病率，危险因素,COVID-19后病情研究和影响评估（PRIME）是一项基于人群的COVID-19测试成年人样本。2021年，61655名成年人被邀请完成在线调查问卷，包括44个症状加上每个症状的严重程度评分（0-10）。患病率是在阳性和阴性测试的成年人中计算的，按COVID-19测试以来的时间分层（3-5、6-11或≥12个月前）。
■在阳性个体中（n=7405，75.6％），根据6个定义，长期症状的患病率在26.9%至64.1%之间，而在阴性个体中(n=2392，24.4%)，患病率在11.4%和32.5%之间。可能归因于COVID-19的长期症状的患病率为17.9%至26.3%。
■当使用不同的COVID-19后条件定义时，患病率估计值存在（实质性）差异，正如目前的做法一样；定义之间存在有限的重叠，这表明COVID-19后的基本病情标准仍不清楚。包括阴性对于确定可归因于COVID-19的长期症状很重要。
■ClinicalTrials.gov标识符：NCT05128695。
